Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
F Huemer,L Weiss,P Regitnig,T Winder,C A Schmitt,J Thaler,E Wöll,R Greil
